Abstract

BackgroundHepatic steatosis (HS), the most frequent liver disorder, was reported to be an independent predictor of cardiovascular disease. HS, if combined with the metabolic syndrome (MetS), might have a synergistic effect on low-density lipoprotein (LDL) particle size.MethodsCarotid intima-media thickness (IMT) and plaque formation, and HS were diagnosed ultrasonographically, and the MetS was diagnosed using the ATP III criteria in 274 healthy workers (mean age ± SD, 43.5 ± 7.1 yrs). LDL particle size was measured with density gradient ultracentrifugation, and subfractions were classified as large, buoyant LDL I (27.2~28.5 nm) and small, dense LDL III (24.2~25.5). All participants were grouped into three categories: control, subjects with HS alone and those with both HS and the MetS.ResultsThe subjects with HS alone were 84 (30.7%), whereas those with HS and the MetS were 46 (16.8%). LDL peak particle sizes showed significant negative correlations with carotid mean IMTs. LDL peak particle size and LDL I (%) decreased significantly in the HS, showing the lowest values in the subjects with both HS and the MetS, and their association was independent, even adjusted for potential confounders. LDL III also showed independent associations across the groups.ConclusionHS alone was more prevalent than HS combined with the MetS in general population. For the patients with HS alone, LDL particle size and carotid atherosclerosis were found to fall in the middle of the control and those with both HS and the MetS.

Highlights

  • Atherosclerosis and its relevant vascular events including cardiovascular disease (CVD), stroke, and peripheral arterial disease (PAD) have become a leading cause of disability and mortality in modern society [1]

  • It is hypothesized that hepatic steatosis (HS) could be associated with variable degrees of atherogenic dyslipidemia, and both low-density lipoprotein (LDL) particle size and carotid atherosclerosis might be exacerbated if HS was combined with the metabolic syndrome (MetS)

  • Among the 293 participants, 15 (5.1%) subjects who had the MetS with no combined HS and 4 (1.4%) who did not undergo abdominal ultrasonographic examinations were excluded from the present study

Read more

Summary

Introduction

Atherosclerosis and its relevant vascular events including cardiovascular disease (CVD), stroke, and peripheral arterial disease (PAD) have become a leading cause of disability and mortality in modern society [1]. A lifestyle summarized as a lack of physical activity and moderate-tohigh intake of calories seems to be one of the most important causes of rapidly increasing prevalence of the metabolic syndrome (MetS) [3], type 2 diabetes mellitus (DM) [4], dyslipidemia [5], and eventually atherothrombotic diseases [2]. It is hypothesized that hepatic steatosis (HS) could be associated with variable degrees of atherogenic dyslipidemia, and both LDL particle size and carotid atherosclerosis might be exacerbated if HS was combined with the MetS. HS, the most frequent liver disorder, was reported to be an independent predictor of CVD [14]. Hepatic steatosis (HS), the most frequent liver disorder, was reported to be an independent predictor of cardiovascular disease. HS, if combined with the metabolic syndrome (MetS), might have a synergistic effect on low-density lipoprotein (LDL) particle size

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call